Coherus To Present Randomized Phase 2 Study Evaluating The Combination Of Casdozokitug, Toripalimab And Bevacizumab In Patients With Liver Cancer

BenzingaDec 18 21:45

Biosimilars Market Industry Trends and Global Forecasts to 2035, Featuring Amgen, BIOCAD, Biocon, Celltrion, Coherus BioSciences, Eli Lilly, Fresenius Kabi, Pfizer, Sandoz and Teva Pharmaceuticals - ResearchAndMarkets.com

BusinesswireDec 10 22:48

TD Cowen Reaffirms Their Buy Rating on Coherus Biosciences (CHRS)

TipRanksDec 6 00:53 · Ratings

Coherus BioSciences Price Target Raised to $6.00/Share From $4.00 by Baird

Dow JonesDec 5 21:23 · Ratings

Coherus BioSciences Is Maintained at Outperform by Baird

Dow JonesDec 5 21:23 · Ratings

Coherus Biosciences Announces Board Member Resignation

TipRanksDec 5 05:50